We have previously described an in vitro sensitization (IVS) procedure which enabled the generation of therapeutic T cells from tumor-hearing mice for adoptive immunotherapy.
The procedure involved culture of tumor-draining lymph node (TDLN) cells with irradiated tumor in the presence of interleukin-2 (IL-2). The availability of many recombinant cytokines affords an opportunity to examine their effects on the immune response to tumor. In this study, we investigated the effect of tumor necrosis factor+ ( 
INTRODUCTION
Adoptive immunotherapy with sensitized T lymphocytes can mediate the regression of established tumor in a variety of animal models [l-3] . These observations have formed the rationale to evaluate this approach in the treatment of human cancer. However, there are two major obstacles that need to be overcome in developing adoptive immunotherapeutic strategies in man. Foremost is the need to reliably isolate effector cells capable of mediating tumor regression from the cancer patient. Secondly, methods to expand large numbers of antitumor effector cells for clinical therapy are required. We have identified an in vitro sensitization (IVS) method with which therapeutic T lymphoid cells from mice bearing progressively growing tumors can be generated in large quantities [4, 5] . This method involves the stimulation of TDLN cells with irradiated tumor in the presence of IL-2. We have reported that, in the absence of IVS, fresh TDLN cells did not mediate tumor regression after adoptive transfer; however, during IVS culture these cells differentiated into potent therapeutic effector cells. Since therapeutic IVS effector cells cannot be generated from lymphoid cells of normal animals, progressive tumor growth must stimulate an immune response within the host. We have termed these lymphoid cells, "preeffector" cells. Using these principles, we are currently evaluating the tumor reactivity of human IVS cells in a clinical trial [6] .
Experimentally, tumor regression mediated by adoptively transferred T effector cells is dose related. To date, clinical experience of adoptive immunotherapy in man has been logistically cumbersome and labor intensive in order to generate large numbers of effector cells for therapy. Nevertheless, initial results from these studies have provided optimism that the theoretical basis of this approach has clinical utility [7, 81. Current investigations are being directed to isolate more potent antitumor reactive cells (i.e., tumor-specific T cells) or enhance their in vivo function. Our adoptive immunotherapy animal model involves three distinct steps: (1) elicitation of preeffector cells in the tumor-bearing host, (2) in vitro differentiation and expansion of therapeutic cells in IVS culture, and (3) mediation of tumor regression by IVS cells after adoptive transfer. We have examined the effect of TNFa within each of these components to determine if TNFa may be a useful adjunct.
TNFa is primarily a macrophage product which was described by its ability to induce hemorrhagic necrosis and regression of some solid tumors [9, lo] . TNFa has also been found to have multiple immunomodulating properties which make it relevant for study in enhancing the host immune response to tumor. TNFcx has been 
MATERIALS AND METHODS
Mice. Female C57BL/6J (B6) mice, 8 to 12 weeks old, were obtained from the Jackson Laboratory (Bar Harbor, ME). Caged in groups of six or fewer, the animals were fed laboratory chow and were given water ad libitum.
Tumor. The MCA 106 sarcoma is a methylcholanthrene-induced tumor of B6 origin. A large number of vials of this tumor from the first passage generation were cryopreserved. After thawing from storage, this tumor was transplanted by subcutaneous (SC) inoculation in syngeneic mice and always used within the first seven transplant generations. Single-cell suspensions were prepared from solid tumors by digestion with constant stirring in 40 ml of Hanks' balanced salt solution (HBSS) (GIBCO, Grand Island, NY) containing 4 mg deoxyribonuclease, 40 mg collagenase, and 100 U hyaluronidase (Sigma Chemical Co., St. Louis, MO) for 3 hr at room temperature [4] .
For establishing solid tumors, B6 mice were inoculated SC in the footpad with 5 X lo5 to lo6 MCA 106 sarcoma cells in 0.05 ml of HBSS. The growth of tumors was evident on Day 3 and, if allowed to grow, all animals would eventually succumbed to the progressively growing tumor with a median survival time of approximately 23 days.
TDLN cell suspensions. Popliteal lymph node draining sites of growing tumor were removed asceptically. Single-cell suspensions were prepared mechanically by pressing the blunt end of a lo-ml plastic syringe plunger in HBSS. The cell suspension was filtered through a layer of No. 100 nylon mesh, (Nytex, TETKO Inc., Briarcliff Manor, NY), washed twice, and suspended in appropriate medium for culture.
Recombinant cytokines. Recombinant human TNFa and recombinant human IL-2 were generously provided by the Cetus Corp. (Emeryville, CA). TNFcv had a specific activity of 2.2 X 10' units/mg as determined by the murine L929 cytolytic bioassay and had an endotoxin level of 0.2 ng/2.2 X lo7 units of TNFa measured by the standard Limulus assay. In vivo administration of TNFa was via intravenous (iv) injection into the tail vein in 1.0 ml of HBSS contain 0.2% of pooled normal mouse serum.
Purified IL-2 had a specific activity of 3 X lo6 Cetus units/mg and an endotoxin level of ~0.1 ng/106 units of IL-2 as measured by the standard Limulus assay. One Cetus unit of IL-2 is equivalent to 6 international units. All units of IL-2 in this report are expressed in Cetus units.
IVS of lymphoid cells with tumor cells and IL-2. The procedures for IVS have been detailed previously (4). Briefly, 6 X lo5 lymph node cells were cultured with lo5 MCA 106 irradiated (4000R) tumor cells in the presence of 10 U/ml recombinant IL-2 in 2 ml of complete medium (CM) in 24-well plates. The composition of CM has been described elsewhere (4). The cultures were incubated at 37"C, 5% CO,, and were fed with 1.0 ml of CM containing 10 U/ml of recombinant IL-2 approximately 5 days later. These cells were routinely harvested on Days 9-11 when they grew to a high density. These cells were washed three times before resuspending in HBSS for adoptive immunotherapy.
Adoptive immunotherapy model. B6 mice were injected iv with 8 X lo6 MCA 106 sarcoma cells in 1.0 ml HBSS to establish pulmonary metastases. On Day 3 or 4, when multiple foci of pulmonary metastases were microscopically evident, therapy was instituted with IVS Iymphoid cells given in 1.0 ml of HBSS through the tail vein. Mice were also injected intraperitoneally (ip) with recombinant IL-2 (7500 U) in 0.5 ml of HBSS, twice a day for 3 to 4 days starting on the day of cell transfer. In all experiments, at least five mice were included in each treatment group. At Days 14 to 16 after tumor inoculation, the mice were ear-tagged, randomized, and then sacrificed for enumeration of metastatic pulmonary nodules as previously described [ 161. Metastases of the sarcoma form white nodules on the blackened surface of the lung (insufflated with a 15% solution of India ink) when "bleached" by Fekette's solution. Nodules were counted in a double-blind fashion without knowledge of the treatment of that mouse. Mice with metastatic foci too numerous to count were assigned an arbitrary value of a250 because this was the largest number of nodules that could be reliably enumerated per lung.
Statistics. The Wilcoxon rank test was used to determine the significance of differences in numbers of pulmonary metastases between treatment groups. Twosided P values are presented. No mice were excluded from the statistical evaluation. footpad tumors measured approximately 5-6 mm in diameter (Table 1) . Five days after TNFa administration, TDLN preeffector cells were harvested for IVS culture. At 8 wg TNFa, significant tumor regression in the footpads was observed compared to control animals; and was associated with a decreased TDLN cell yield per node (Table 1) . We have previously shown that TDLN preeffector cells are not capable of mediating tumor regression when freshly harvested and require IVS culture to acquire therapeutic efficacy. Therefore, in order to assess for the development of preeffector cells, TDLN cells were cultured by the IVS method and subsequently assayed for antitumor activity in adoptive immunotherapy experiments.
After IVS culture, cells were adoptively transferred into mice bearing 3-or 4-day established pulmonary metastases (Table 2 ). Low dose IL-2 was administered ip in conjunction with IVS cells since it has been previously shown to facilitate in uiuo proliferation of the transferred cells [17, 181. These doses of IL-2 alone did not mediate antitumor effects. In order to assess differences in preeffector cell activity between groups of animals, IVS effector cells were adoptively transferred at various doses. Preeffector cells from mice not treated with TNFa were capable of differentiating into potent IVS cells as seen in Table 2 . However, there was significant inhibition of preeffector cell activity in all groups of animals receiving TNFcu. The lowest dose of TNFa, 0.5 pg, resulted in diminished preeffector cell activity compared to animals not receiving TNFa. There was no apparent difference in the amount of inhibition with the higher doses of TNFa.
A kinetic study of the TNFa effect on preeffector cell activity was performed (Table 3) . On Days 7,11, and 14 after tumor inoculation, 2 pg TNFa was administered iv, and TDLN harvested for IVS culture on Day 20. Subsequent IVS cells were assessed for antitumor reactivity in the adoptive immunotherapy of 3-day pulmonary metastases. There was increasing suppression of preeffector cell activity the later the TNFcY was administered.
Effect of TNFa on the Differentiation of Preeffector Cells during IVS Culture
We have shown that preeffector cells mature into functional antitumor effector cells during IVS culture. The antitumor reactivity of IVS cells in adoptive immunotherapy can be enhanced by altering the IL-2 concentration in the IVS culture [ 191. Low concentrations of IL-2 (2-10 U/ml) resulted in more potent IVS effector cells on a per cell basis than cells cultured in high concentrations of IL-2 (100-1000 U/ml). We examined whether the functional antitumor reactivity of preeffector cells would be altered by the addition of TNFa in the IVS culture system. Preeffector cells were harvested from mice bearing MCA 106 footpad tumor initiated 15 days earlier and placed in IVS culture. TNFa! was added at various concentrations (10, 100, 1000 U/ml) at the initiation of the IVS cultures which also included a standard concentration of IL-2 (10 U/ml). IVS cells generated without added TNFa expanded 1.2fold over 11 days. IVS cells generated at 10, 100, and 1000 U/ml of TNFa! expanded 1.8-, 1.6-, and 0.9-fold during this same time interval. The IVS cells were then assayed for antitumor efficacy by the adoptive immunotherapy of 3-day 174 (40) a IVS cells were administered iv into mice with 3-day-established pulmonary metastases. All mice received IL-2 7500 U ip twice daily for six doses commencing with the adoptive transfer of IVS cells.
* TNFol was administered iv at 4,2, and 2 pg on the day of adoptive cell transfer in Experiments 1, 2, and 3, respectively. ' Experiment 3 involves therapy of 3-day MCA 203 pulmonary metastases by IVS cells (5 X 105, 1.25 X 105) derived from MCA 203 tumor-bearing mice. IVS culture and adoptive immunotherapy were performed in a manner similar to that of Experiments 1 and 2.
d P < 0.05 compared to the group that received IL-2 only. e P < 0.05 compared to the group that received IL-2 and TNFn.
'P < 0.05 compared to the group that received IVS cells and IL-2.
Effect of TNFa on the Antitumor Activity of Adoptively Transferred IVS Cells   TABLE 4 Effect of TNFcr on the in Vitro Generation of IVS Cells
IVS Cells" TNFolb
Mean pulmonary metastases (SEM) 128 (37) 6 x lOa 2 (1)" 1.5 x 10" 27 (7)' 3.8 x lo5
121 (22) 6 X lo6 10 2 (tl)' 1.5 x lo6 10 77 (36) 3.8 x lo5 10 150 (30) 6 X lo6 100 5 (2)' 1.5 x 106 100 28 (5)' 3.8 x lo5 100 123 (29) 6 x lo6 1000 8 (3)" 1.5 x 106 1000 67 (16) 3.8 x lo5 1000 144 (51) a Mice inoculated with 5 X lo5 MCA 106 in the footpad and TDLN cells harvested 15 days later for IVS culture. IVS cells were transferred iv into mice with established 3-day MCA 106 pulmonary metastases. All mice received 7500 U IL-2 ip twice daily for six doses commencing with the adoptive transfer of IVS cells.
b TNFol was added to IVS cultures at: 1, 10,100, and 1000 U/ml (1 U = 4.55 x 10m5 pg TNFa).
' P < 0.05 compared to the group that did not receive IVS cells.
We have shown that exogenous IL-2 given ip will enhance the antitumor efficacy of transferred IVS cells [4] . The enhancing effect of IL-2 has been shown to be due to increased proliferation and survival of the transferred cells [ 181. We examined the effect of TNFa administration on the therapeutic efficacy of IVS cells plus IL-2 treatment of MCA 106 pulmonary metastases (Table 5) . TNFa (2-4 pg) was administered iv in conjunction with the transferred cells. These doses of TNFa were nontherapeutic in mediating regression of pulmonary metastases. In mice receiving IVS cells plus IL-2 there was significant regression of pulmonary metastases which was proportional to the number of cells. The addition of TNFa enhanced the antitumor efficacy mediated by the IVS cells plus IL-2.
DISCUSSION
Studies demonstrating that neoplastic cells express antigens capable of inducing tumor-specific immune responses has provided the rationale for developing immunotherapeutic approaches to cancer. Experimentally, the adoptive transfer of immune T cells has resulted in significant tumor regression and cures in animals with advanced visceral tumors. Once cured, these animals often exhibit systemic tumor immunity by the rejection of subsequent tumor challenges. We have developed a [7, 81 . These efforts have proven to be very labor intensive and difficult. Therefore, methods to enhance the generation or antitumor reactivity of effector T cells has been an area of active investigation.
The availability of recombinant cytokines has enabled investigators to modulate in vitro and in uiuo immune responses. We sought to evaluate the adjuvant effect of TNFa in enhancing the tumor reactivity of T cells in our adoptive immunotherapy model. Besides its tumoricidal activity, TNFa is a cytokine which has diverse immunomodulatory effects. TNFa! has been reported to activate neutrophils and macrophages; enhance natural killer and LAK cell activity; upregulate MHC and tumor-associated antigen expression; upregulate intercellular adhesion cell surface molecules; and increase IL-2 receptor expression [11-l& 201 . In addition, TNFol has been shown to act as an adjuvant to the development of cytolytic T cells responding to tumor immunization [15] . These findings established the rationale to investigate the effect of TNFa on the: (1) in uiuo development of preeffector cells in the tumor-bearing host; (2) in vitro maturation of preeffector cells into effector cells during IVS culture and; (3) in uiuo antitumor efficacy of IVS effector cells.
We have previously reported that the TDLN is the site where preeffector cells elicited in response to weakly immunogenic tumors can be reliably retrieved [4, 5] . For the weakly immunogenic tumors such as MCA 106, preeffector cells in the TDLN are evident as early as 4 days after tumor inoculation and persist out to Day 21. We found that TNFo (0.5-8.0 pg/animal) given 14 days after tumor inoculation significantly inhibited preeffector cell activity. Preeffector cell activity was assessed by harvesting TDLN cells for IVS culture and measuring their antitumor reactivity in adoptive immunotherapy experiments. There was no apparent relationship between the amount of TNFa administered and the degree of preeffector cell inhibition.
In a separate experiment TNFcx administered 7 and 11 days after tumor inoculation was not as effective in inhibiting preeffector cells compared to animals that receive TNFa on Day 14. One possible explanation is that TNFa! inhibited the development of preeffector cells and that earlier TNFa exposure enabled recovery of the tumor-bearing host to develop an immune response to tumor in the TDLN. It was also possible that TNFa inactivated or suppressed already developed preeffector cells within the TDLN.
In order to investigate the latter possibility, TNFcx was added to IVS cultures initiated with established preeffector TDLN cells. TNFa (10-1000 U/ml) neither suppressed nor enhanced the maturation of preeffector cells into IVS effector cells which were assessed in adoptive immunotherapy experiments. Concentrations of TNFQ in IVS culture were comparable to plasma concentrations achieved in mice (assuming a 2-ml blood volume per animal) that inhibited preeffector cell activity. These findings would indicate that TNFa! administration in the tumor-bearing host resulted in the inhibition of preeffector cell development within the TDLN.
TNFor and interferon-y has been reported to synergistically enhance the in uiuo antitumor efficacy of TIL and IL-2 therapy [al] . We examined the effect of TNFa administration on the antitumor activity of IVS cells and IL-2. At a nontherapeutic dose of TNFa, there was enhanced tumor regression mediated by IVS cells and IL-2. Our laboratory has previously shown that the administration of interferon-a (IFNa) significantly enhanced the antitumor efficacy of IVS cells in the treatment of MCA 106, but not MCA 203, pulmonary metastases [22] . In that study we found that IFNa pretreatment of MCA 106 tumor cells resulted in increased lysis by IVS cells in a 4-hr chromium release assay which was not evident for the MCA 203 tumor. Similarly, the mechanism by which TNFa! enhanced the antitumor function of IVS cells may be to increase the susceptibility of tumor lysis by effector T cells. Others have reported that specific tumor lysis of cultured tumor targets by TIL in a similar cytotoxicity assay was increased by pretreatment with TNFa [21, 231.
The focus of these studies was to examine the influence of TNFa in modulating the immune response to tumor in order to improve the therapeutic potential of IVS cell therapy. TNFa was found to have divergent effects in our experimental model and underscores the multiple sites of interaction where immune modulators may or may not play a beneficial role. At the preeffector cell phase, TNFa! was found to inhibit their development within the TDLN. Preliminary studies in our laboratory have indicated that other immune modulators such as IL-la or Corynebacterium paruum can augment preeffector cell generation. During the in vitro sensitization phase, TNFa did not alter preeffector cell maturation into therapeutic effector cells. We have previously reported that the antitumor efficacy of IVS cells is dependent upon the concentration of IL-2 used during IVS culture (19). Lower concentrations of IL-2 (2-10 U/ml) resulted in more potent effector cells compared to higher (100-1000 U/ml) concentrations.
The effect of other cytokines within this culture system needs to be further defined. At the effector cell phase, TNFa was found to augment the antitumor reactivity of IVS cells given in conjunction with IL-2, and may be a useful adjunct for
